Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL.

Fava M, Rush AJ, Thase ME, Clayton A, Stahl SM, Pradko JF, Johnston JA.

Prim Care Companion J Clin Psychiatry. 2005;7(3):106-13.

2.

Bupropion: a review of its use in the management of major depressive disorder.

Dhillon S, Yang LP, Curran MP.

Drugs. 2008;68(5):653-89. Review. Erratum in: Drugs. 2008;68(7):980.

PMID:
18370448
3.

A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor.

Stahl SM, Pradko JF, Haight BR, Modell JG, Rockett CB, Learned-Coughlin S.

Prim Care Companion J Clin Psychiatry. 2004;6(4):159-166.

4.

Spotlight on bupropion in major depressive disorder.

Dhillon S, Yang LP, Curran MP.

CNS Drugs. 2008;22(7):613-7. Review.

PMID:
18547129
5.

A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline.

Croft H, Settle E Jr, Houser T, Batey SR, Donahue RM, Ascher JA.

Clin Ther. 1999 Apr;21(4):643-58.

PMID:
10363731
6.

Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.

Foster RH, Goa KL.

CNS Drugs. 1997 Aug;8(2):163-88. doi: 10.2165/00023210-199708020-00010.

PMID:
23338224
7.

Bupropion sustained release: side effect profile.

Settle EC Jr.

J Clin Psychiatry. 1998;59 Suppl 4:32-6. Review.

8.

Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations.

Jefferson JW, Pradko JF, Muir KT.

Clin Ther. 2005 Nov;27(11):1685-95. Review.

PMID:
16368442
9.
10.

Bupropion extended-release for depressive disorders.

Jefferson JW.

Expert Rev Neurother. 2008 May;8(5):715-22. doi: 10.1586/14737175.8.5.715. Review.

PMID:
18457528
11.

Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.

Hewett K, Gee MD, Krishen A, Wunderlich HP, Le Clus A, Evoniuk G, Modell JG.

J Psychopharmacol. 2010 Aug;24(8):1209-16. doi: 10.1177/0269881109106953. Epub 2009 Nov 25.

PMID:
19939870
12.

Duloxetine: a review of its use in the treatment of generalized anxiety disorder.

Carter NJ, McCormack PL.

CNS Drugs. 2009;23(6):523-41. doi: 10.2165/00023210-200923060-00006. Review.

PMID:
19480470
13.

Bupropion sustained release versus paroxetine for the treatment of depression in the elderly.

Weihs KL, Settle EC Jr, Batey SR, Houser TL, Donahue RM, Ascher JA.

J Clin Psychiatry. 2000 Mar;61(3):196-202.

PMID:
10817105
14.

The efficacy and tolerability of bupropion in the treatment of major depressive disorder.

Moreira R.

Clin Drug Investig. 2011 Oct 19;31 Suppl 1:5-17. doi: 10.2165/1159616-S0-000000000-00000. Review.

PMID:
22015858
15.

Antidepressants for smoking cessation.

Hughes JR, Stead LF, Hartmann-Boyce J, Cahill K, Lancaster T.

Cochrane Database Syst Rev. 2014 Jan 8;(1):CD000031. doi: 10.1002/14651858.CD000031.pub4. Review.

PMID:
24402784
16.

Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients.

Kavoussi RJ, Segraves RT, Hughes AR, Ascher JA, Johnston JA.

J Clin Psychiatry. 1997 Dec;58(12):532-7.

PMID:
9448656
17.

Prevalence of sexual dysfunction among newer antidepressants.

Clayton AH, Pradko JF, Croft HA, Montano CB, Leadbetter RA, Bolden-Watson C, Bass KI, Donahue RM, Jamerson BD, Metz A.

J Clin Psychiatry. 2002 Apr;63(4):357-66.

PMID:
12000211
18.

Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies.

Clayton AH, Croft HA, Horrigan JP, Wightman DS, Krishen A, Richard NE, Modell JG.

J Clin Psychiatry. 2006 May;67(5):736-46.

PMID:
16841623
19.

Second-generation antidepressants for preventing seasonal affective disorder in adults.

Gartlehner G, Nussbaumer B, Gaynes BN, Forneris CA, Morgan LC, Kaminski-Hartenthaler A, Greenblatt A, Wipplinger J, Lux LJ, Sonis JH, Hofmann J, Van Noord MG, Winkler D.

Cochrane Database Syst Rev. 2015 Nov 8;(11):CD011268. doi: 10.1002/14651858.CD011268.pub2. Review.

PMID:
26558418
20.

Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.

Garnock-Jones KP, Keating GM.

Paediatr Drugs. 2009;11(3):203-26. doi: 10.2165/00148581-200911030-00005. Review.

PMID:
19445548

Supplemental Content

Support Center